Course Experts: Lucy Yu, PharmD, BCPS, BCOP and Gayle Blouin, PharmD, BCOP

Course Description: This course reviews platinum resistant ovarian cancer, key trial endpoints related to approval of mirvetuximab soravtansine (MIRV), prevention of common ocular toxicities, and application of current evidence to patient care and decision-making.